Robust isolation of malignant plasma cells in multiple myeloma.
(2014) In Blood 123(9). p.1336-1340- Abstract
- Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable... (More)
- Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4292197
- author
- Frigyesi, Ildiko
LU
; Adolfsson, Jörgen
LU
; Ali, Mina
LU
; Christophersen, Mikael Kronborg
LU
; Johnsson, Ellinor
LU
; Turesson, Ingemar
LU
; Gullberg, Urban
LU
; Hansson, Markus
LU
and Nilsson, Björn LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 123
- issue
- 9
- pages
- 1336 - 1340
- publisher
- American Society of Hematology
- external identifiers
-
- pmid:24385542
- wos:000335839300016
- scopus:84899692195
- pmid:24385542
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2013-09-529800
- project
- Genetic predisposition for multiple myeloma
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Clinical Genetics (013022003), Emergency medicine/Medicine/Surgery (013240200), Division of Hematology and Transfusion Medicine (013041100)
- id
- c3e71216-e4d1-436a-8943-862eed761439 (old id 4292197)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24385542?dopt=Abstract
- date added to LUP
- 2016-04-01 10:14:21
- date last changed
- 2024-10-06 23:51:13
@article{c3e71216-e4d1-436a-8943-862eed761439, abstract = {{Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.}}, author = {{Frigyesi, Ildiko and Adolfsson, Jörgen and Ali, Mina and Christophersen, Mikael Kronborg and Johnsson, Ellinor and Turesson, Ingemar and Gullberg, Urban and Hansson, Markus and Nilsson, Björn}}, issn = {{1528-0020}}, language = {{eng}}, number = {{9}}, pages = {{1336--1340}}, publisher = {{American Society of Hematology}}, series = {{Blood}}, title = {{Robust isolation of malignant plasma cells in multiple myeloma.}}, url = {{http://dx.doi.org/10.1182/blood-2013-09-529800}}, doi = {{10.1182/blood-2013-09-529800}}, volume = {{123}}, year = {{2014}}, }